Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 18/20 | 0.55 |
| ▸ | DRD3 | P35462 | 17/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30964278 | 0.84 | CXCR3 (0.55) | DRD2DRD3 | |
| SCHEMBL30964285 | 0.79 | TRPV1 (0.52) | DRD2DRD3 | |
| SCHEMBL30964290 | 0.74 | DRD3 (0.55) | DRD2DRD3 | |
| SCHEMBL30964310 | 0.72 | TRPV1 (0.51) | DRD2DRD3 | |
| SCHEMBL16464148 | 0.71 | DRD3 (1.00) | DRD2DRD3 | |
| SCHEMBL29104598 | 0.70 | KMT2A (0.67) | — | |
| SCHEMBL13930797 | 0.69 | CHRM4 (0.60) | — | |
| SCHEMBL27237946 | 0.69 | DRD2 (0.60) | DRD2DRD3 | |
| SCHEMBL30965800 | 0.68 | DRD2 (0.58) | DRD2DRD3 | |
| SCHEMBL3799761 | 0.68 | KMT2A (0.67) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076975-A1 | TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2026-03-19 | — | — | US | disclosed |
| EP-4628098-A1 | TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| CN-118121699-A | TPK agonists and methods of using the same for treating neurodegenerative diseases | 上海日馨医药科技股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076975-A1 | TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES | PDXK, NADK, HYPK | DRD2 2783/4885DRD3 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.